VivoSeq
Other

Gastric Emptying

0

Pipeline Programs

1

Active Trials

8

Companies Involved

Gastric Emptying is an early-stage landscape with 0 programs across 8 companies. The most active players are GSK, Novo Nordisk, Takeda.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

28

clinical trials

Completed24 · 86%
Unknown status2 · 7%
Terminated1 · 4%
Not yet recruiting1 · 4%

Trial Activity

28 trials

Effect of Teduglutide on Gastric Emptying in Healthy Subjects
Completed·Takeda logoTakeda·Phase 1·NCT01209351·36 enrolled
Evaluation of Apraglutide on Gastric Emptying
Completed·VVectivBio AG·Phase 1·NCT05995704·42 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)